Status
The evidence base at a glance.
3
Species-level clinical publications
5
Strain-specific research endpoints
2
Peer-reviewed papers on MTCC 25308
Study 01
Bacillus coagulans MTCC 5856 in diarrhoea-predominant IBS
Design
Randomized, double-blind, placebo-controlled pilot study
Strain
MTCC 5856
Reported outcome
Reductions in abdominal pain, bloating, flatulence and diarrhoea; improvements in stool consistency and overall IBS symptom scores.
Reference
Majeed M. et al. Nutrition Journal. 2016;15:21.
Study 02
Bacillus coagulans in acute diarrhoea
Design
Human clinical investigation in acute diarrhoea
Strain
B. coagulans, species level
Reported outcome
Reduced duration and frequency of diarrhoea, faster restoration of normal bowel habits and improved gut comfort.
Reference
Sudha M.R., Bhonagiri S. Int. J. Probiotics Prebiotics. 2012;7(1):33-37.
Study 03
Digestive health and immune function
Design
Clinical publication summary
Strain
B. coagulans, species level
Reported outcome
Improved intestinal microbial balance, suppression of pathogens, reductions in inflammatory markers and improved immune response.
Reference
Majeed M. et al. Journal of Clinical Gastroenterology. 2018;52(Suppl 1):S41-S46.
Principle
Strain-level precision.
Probiotic activity is strain-specific, which is why every study on this site is labelled by the exact strain evaluated. Bacospore® is MTCC 25308; the randomized IBS study above used MTCC 5856. Our communications separate strain-specific Bacospore® evidence, species-level B. coagulans research and wider Bacillus category science, so your technical and regulatory teams always know which source sits behind which statement.